TroyGould Attorneys Sign TroyGould Attorneys Sign

TroyGould Represents Lion Biotechnologies in $73.6 Million Public Offering

TroyGould PC represented Lion Biotechnologies, Inc., a clinical-stage biopharmaceutical company focused on the development and commercialization of novel cancer immunotherapy products, in connection with its public offering of 9,200,000 shares of Lion’s common stock at $8 per share. The deal closed on March 3, 2015, with gross proceeds of $73.6 million.

Istvan Benko lead the transaction with the assistance of associate Dietrick Miller.

Jefferies LLC and Cowen and Company, LLC, and Piper Jaffray & Co. acted as the joint book-running managers of the offering, and Roth Capital Partners, LLC acted as co-manager.

Latham & Watkins LLP in San Diego represented the underwriters.